Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AGIO | 144 | neutral | 2/10 | Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 notice of intent to sell 7,866 shares of common sto | Oct 26, 2026 |
| TPST | DEF 14A | bearish | 6/10 | Tempest Therapeutics' 2026 definitive proxy statement schedules a November 9, 2026 annual meeting with four proposals: e | Oct 26, 2026 |
| SAFX | DEF 14A | bearish | 6/10 | XCF Global (SAFX) is holding a special meeting on November 9, 2026 to approve a reverse stock split (1-for-2 to 1-for-50 | Oct 26, 2026 |
| CTXR | 8-K | neutral | 4/10 | Citius Oncology reported preliminary Q4 FY2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 360 uni | Oct 26, 2026 |
| CTOR | 8-K | neutral | 5/10 | Citius Oncology reported preliminary fiscal Q4 2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 36 | Oct 26, 2026 |
| JAZZ | 8-K | bearish | 6/10 | Jazz Pharmaceuticals filed an 8-K estimating a pre-tax charge of approximately $755 million for acquired IPR&D expense r | Oct 26, 2026 |
| ASND | 6-K | bullish | 5/10 | Ascendis Pharma announced pooled data from Phase 2 and Phase 3 trials showing TransCon PTH (palopegteriparatide) provide | Oct 26, 2026 |
| SPRC | 6-K | bearish | 5/10 | SciSparc entered into an inducement letter with L.I.A Pure Capital to exercise warrants for 405,728 shares at a reduced | Oct 26, 2026 |
| SNY | SC 13G/A | neutral | 2/10 | Amundi filed an amended Schedule 13G disclosing a 5.70% passive stake in Sanofi as of September 30, 2026, up from 5.50% | Oct 26, 2026 |
| LONA | SC 13D/A | neutral | 3/10 | Perceptive Advisors LLC filed an amended Schedule 13D disclosing that its affiliate, Perceptive Xontogeny Venture Fund I | Oct 26, 2026 |
| SAFX | 3 | neutral | 1/10 | Chad J. Langley filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing no securities benef | Oct 26, 2026 |
| HELP | 3 | neutral | 2/10 | Freda C. Lewis-Hall filed a Form 3 initial statement of beneficial ownership after becoming a director of Helus Pharma I | Oct 26, 2026 |
| CTOR | PRESS-RELEASE | neutral | 4/10 | Citius Oncology reported preliminary Q4 FY2026 unit sales of 792 LYMPHIR units to U.S. wholesalers, a 120% increase from | Oct 26, 2026 |
| NRSN | 6-K | neutral | 3/10 | NeuroSense Therapeutics announced a strategic collaboration with an advisor to supply PrimeC, its ALS drug candidate, to | Oct 26, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly transactions under its ongoing DKK 15 billion share repurchase progra | Oct 26, 2026 |
| GSK | 6-K | bullish | 5/10 | GSK announced positive Phase III data for Ris-Rez (risvutatug rezetecan) in relapsed osteosarcoma from the ARTEMIS-011 t | Oct 26, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting that Maya Martinez-Davis, President US, acquired 9.324 notional ADS at $51.21 within her | Oct 26, 2026 |
| LLY | PRESS-RELEASE | neutral | 2/10 | Eli Lilly declared a Q4 2026 dividend of $1.73 per share, payable December 10, 2026, to shareholders of record on Novemb | Oct 26, 2026 |
| HELP | 3 | neutral | 2/10 | Amir Inamdar filed a Form 3 initial statement of beneficial ownership, reporting 224,332 common shares held indirectly v | Oct 26, 2026 |
| SAFX | 3 | neutral | 2/10 | Carl Stanton filed a Form 3 initial statement of beneficial ownership with XCF Global, Inc. (SAFX), disclosing deemed be | Oct 26, 2026 |
| XBIT | 8-K | neutral | 3/10 | XBiotech Inc. filed an 8-K announcing the appointment of Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive | Oct 26, 2026 |
| AKBA | PRESS-RELEASE | bullish | 6/10 | Akebia Therapeutics announced positive VOICE trial data for Vafseo (vadadustat) presented at ASN Kidney Week, showing st | Oct 26, 2026 |
| NEOG | 8-K/A | neutral | 2/10 | This 8-K/A amends the original 8-K filed on October 7, 2026, to add Item 5.02 disclosure regarding shareholder approval | Oct 26, 2026 |
| LGVN | PRESS-RELEASE | mixed | 6/10 | Longeveron announced updated results from its Phase 2b ELPIS II trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K to report that its Chief Business Officer presented a research framework (Partitione | Oct 26, 2026 |
| AZTR | 8-K | neutral | 4/10 | Azitra announced positive ex vivo data for its ATR-COSF cosmetic product candidate, showing up to ~50% reduction in fine | Oct 26, 2026 |
| IDXX | INST-CLUSTER | neutral | 3/10 | Three asset managers added to IDXX positions in Q3 2026, totaling $43.2M in net buying, while two managers trimmed $69.4 | Oct 26, 2026 |
| WST | INST-CLUSTER | neutral | 3/10 | Four institutional asset managers added to WST positions in Q3 2026, totaling $11.8M in net buying, while three smaller | Oct 26, 2026 |
| EQ | PRESS-RELEASE | neutral | 4/10 | Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral AhR modulator for inflammatory diseases, triggeri | Oct 26, 2026 |
| BAK | 6-K | bearish | 6/10 | Braskem filed a 6-K disclosing confidential restructuring proposals exchanged with bondholders in its out-of-court reorg | Oct 26, 2026 |